Nimbus Therapeutics last made headlines in 2016, when the Cambridge-based company sold a drug for the liver disease NASH to Gilead Sciences (Nasdaq: GILD) for a clean $1.2 billion — including $400 million up front. Since then, the company has quietly shifted its focus to autoimmune disease drugs, targeting the skin disorder psoriasis and certain cancers. Nimbus got a boost to those efforts on Monday.
